Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Measles Vaccination Coverage and Seroprevalence of Anti-Measles Antibody in South-East Islamic Republic of Iran; [Couverture Vaccinale Antirougeoleuse Et Seroprevalence Des Anticorps Antirougeoleux Dans Le Sud-Est De La Republique Islamique D'iran] Publisher Pubmed



Izadi S1 ; Mokhtariazad T2 ; Zahraei SM3
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Epidemiology, Health Promotion Research Centre, School of Public Health, Zahedan University of Medical Sciences, Zahedan, Iran
  2. 2. National Reference Laboratory for Measles and Rubella, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
  3. 3. Centre for Communicable Disease Control, Ministry of Health and Medical Education, Tehran, Iran

Source: Eastern Mediterranean Health Journal Published:2015


Abstract

Discrepancies often exist between recorded immunization coverage and the real immunity level in a community. To estimate the vaccination coverage against measles in south-east Islamic Republic of Iran, a crosssectional study was conducted in 3 districts during summer 2011. Using probability proportional to size cluster sampling, 1368 children aged 30–54 months were selected. Serum samples of 663 who had received 2 injections of mumpsmeasles-rubella (MMR) vaccine were checked for anti-measles IgG. Vaccination coverage for the second dose of MMR vaccine was 93.7%. The prevalence of anti-measles IgG in those who had received at least 2 MMR vaccine doses was 94.6%. There was a statistically significant association between the serological results and variables that reflected poor accessibility to health services. Combining serological results with coverage data, the proportion of the community protected against measles was estimated as 88.6%, which was below the limits defined for the measles elimination goals. © 2015, World Health Organization. All rights reserved.
Related Docs
1. Head-To-Head Immunogenicity Comparison of Edmonston-Zagreb Vs. Aik-C Measles Vaccine Strains in Infants Aged 8–12 Months: A Randomized Clinical Trial, Vaccine (2018)
2. Seroconversion Rates Following 2 Doses of Measles- Mumps- Rubella Vaccination Given at the Ages 12 and 18 Months: Data for Possible Additional Dose at Older Age, BMC Immunology (2022)
3. Measles and Rubella Serosusceptibity Among Population Vaccinated With Different Schedules: The Potential Impact on Measles-Rubella Elimination in Iran, BMC Infectious Diseases (2021)
4. Seroprevalence of Antibodies to Measles and Rubella Eight Months After a Vaccination Campaign in the Southeast of Iran, Human Vaccines and Immunotherapeutics (2018)
5. Measles Immunity Status in Iranian Infants and Children and Outbreak Concerns: Time for Reconsidering the Vaccination Schedule?, Vaccine (2024)
6. A Nationwide Study on the Seroprevalence of Measles, Mumps, and Rubella in Iranian Children and Adolescents, Iranian Journal of Public Health (2022)
7. Seroprevalence of Anti-Rubella and Anti-Measles Antibodies in Women at the Verge of Marriage in Iran, Vaccine (2020)
Experts (# of related papers)
View all Related Experts
Hiva Saffar (2)
Samaneh Salarvand (1)